Abstract
In recent years, there has been tremendous interest surrounding the integration of venetoclax into both non-intensive and intensive chemotherapy regimens for AML. However, with this increasing utilization of venetoclax, considerable questions surrounding key issues such as dosing strategies and the practicality of venetoclax administration have arisen. This review highlights the evolution of venetoclax-based regimens in AML and provides a commentary on notable practical considerations when utilizing this agent.
©2024 American Association for Cancer Research.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
-
Bridged Bicyclo Compounds, Heterocyclic* / administration & dosage
-
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
-
Humans
-
Leukemia, Myeloid, Acute* / drug therapy
-
Sulfonamides* / administration & dosage
-
Sulfonamides* / therapeutic use
Substances
-
venetoclax
-
Bridged Bicyclo Compounds, Heterocyclic
-
Sulfonamides
-
Antineoplastic Agents